Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement
Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement...
ADC / XDC
Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...
Tasly Pharmaceuticals Gets NMPA Approval for STRO-002 Clinical Study in Solid Tumors
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...
Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data
Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Sichuan Kelun-Biotech’s SKB264 Achieves Primary Endpoint in Phase III TNBC Study
Sichuan Kelun Pharmaceutical Co., Ltd’s innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:...
WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305
Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing...
InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs
China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-A1811 and Pyrotinib Combo Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...
Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab...
WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...